{"product_id":"roche-ansoff-matrix","title":"Roche  Ansoff Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Roche Ansoff Matrix Analysis gives a clear view of Roche’s growth options across market penetration, market development, product development, and diversification. The page already shows a real preview of the actual report content, so you can review the analysis style before buying. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Penetration\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpanding Vabysmo market share to 28 percent in key ophthalmology segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche is pushing Vabysmo to 28 percent market share in key ophthalmology segments by winning patients from older anti-VEGF drugs with longer dosing intervals. By Q1 2026, Vabysmo had taken over one-quarter of US new patient starts in age-related macular degeneration, backed by real-world evidence showing fewer injections than prior standards of care. That matters because fewer clinic visits can improve persistence and make Vabysmo a stronger first-choice option.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConversion of Ocrevus patients to the subcutaneous 10 minute injection format\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche’s move to convert about 35% of Ocrevus multiple sclerosis patients to a 10-minute subcutaneous injection by 2026 is a clear market-penetration play. It defends the franchise against biosimilars by making treatment easier for clinics and patients, while keeping patients inside Roche’s own ecosystem. Ocrevus was still a blockbuster in 2025, and this switch helps extend that cash flow by raising convenience and switching costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDominating hospital lab capacity with the cobas 8000 modular analyzer series\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche is deepening market penetration in hospital labs by installing over 2,500 cobas 8000 integrated units across top-tier facilities in 2025. The installed base acts as a razor-blade model, with reagent sales from existing customers growing about 7% a year. High-throughput workflow and stable uptime keep cobas 8000 central in high-volume testing, where switching costs are high.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeveraging Polivy frontline data to secure 15 percent more oncology accounts\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche is using updated Polivy frontline DLBCL data to win more US oncology accounts, especially mid-sized community practices that drive large first-line volume. POLARIX showed a 27% lower risk of progression or death and 2-year PFS of 76.7% versus 70.2%, giving sales teams a clear proof point for adding Polivy to R-CHP. That evidence helps Roche deepen technical ties and push Polivy toward gold-standard use across broader patient groups.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustaining a 12 percent share in integrated diabetes management platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche sustains its 12 percent share in integrated diabetes management by linking MySugr with Accu-Chek devices, so glucose data flows into one user path. In 2026, Roche aims to lift engagement by 15 percent among existing device users through automated data syncing, which should deepen daily use and reduce churn. That matters because higher app use supports repeat testing-strip sales and recurring digital subscription revenue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche’s 2025 Growth Engine: Vabysmo, Ocrevus, and cobas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s market penetration in 2025 is driven by Vabysmo, Ocrevus, and cobas 8000, all aimed at taking share from entrenched standards by reducing injections, improving convenience, and raising switching costs. Vabysmo reached about 28% share in key ophthalmology segments, while Ocrevus kept blockbuster scale and the cobas base stayed above 2,500 installed units. That mix supports repeat use and recurring revenue.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003e2025 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVabysmo\u003c\/td\u003e\n\u003ctd\u003e~28% share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOcrevus\u003c\/td\u003e\n\u003ctd\u003eBlockbuster\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ecobas 8000\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;2,500 units\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nOutlines Roche’s growth options across existing and new products and markets\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\nHelps Roche quickly spot growth priorities with a clear Ansoff view of existing and new markets and products.\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eM\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003earket Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAggressive expansion of high-end diagnostic infrastructure in the Chinese healthcare market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche is pushing market development in China by adding 450 diagnostic laboratories in tier-two and tier-three cities by early 2026, extending high-throughput testing into underserved regional hubs. This opens access to millions of patients and supports China’s 280 million people aged 60+ in 2025, a key demand pool for oncology and chronic-disease testing. The move also helps offset pricing pressure in mature Western markets by shifting volume to faster-growing, higher-need local demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntroducing standardized oncology therapies to 12 middle income nations via EASE\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche uses the Expansion of Access and System Effectiveness (EASE) program to move approved biologics into 12 middle-income nations, including Indonesia and Brazil. In 2025, this market-development play targets a 20 percent patient-volume lift versus 2024, using tiered pricing to widen access without building new drugs. It also uses Roche's existing global biologics capacity to serve larger, faster-growing patient pools.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScaling Point of Care molecular testing across rural North American clinics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche is using its cobas Liat point-of-care PCR platform to grow in the US decentralised testing market, where clinics want fast results without sending samples to distant labs. The system can return respiratory results in about 20 minutes, which fits same-day primary care decisions.\u003c\/p\u003e\n\u003cp\u003eThis is a market development move built on an existing product, not a new device, so Roche can scale faster into rural North American clinics. In 2025, Roche Diagnostics remained a core business within group sales of CHF 60.5 billion, giving it the cash and reach to push placement and service coverage.\u003c\/p\u003e\n\u003cp\u003eThe bet is on convenience: patients and clinicians want rapid flu and COVID testing at the point of care, especially outside urban hospitals. If Roche keeps expanding installed units across rural clinics, it can deepen recurring cartridge demand and lock in local testing workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablishing direct diagnostic commercial operations in five sub-Saharan African countries\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche’s move from distributor-led sales to direct subsidiaries in five sub-Saharan African countries is a clear market-development play: it opens new geographies with the same diagnostic portfolio. Direct control over sales and logistics has already cut reagent delivery lead times by 10%, which should improve hospital uptime and buying confidence. As public healthcare budgets rise, faster supply and local service make Roche’s diagnostics more likely to become the default choice.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTailoring cardiovascular diagnostic panels for emerging markets in the Middle East\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche is adapting its high-sensitivity troponin assays for Gulf Cooperation Council markets, where cardiovascular disease remains a top driver of mortality; WHO says CVD caused about 17.9 million deaths globally in 2023. The push is backed by local medical education programs that have reached over 1,500 clinicians, which should speed adoption and test use. By anchoring the platform in specialty clinics in Riyadh and Dubai, Roche can turn an existing assay into a regional standard for acute cardiac care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche Expands Access by Selling More of What Already Works\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s market development in 2025 centers on moving existing diagnostics and biologics into new geographies, especially China’s lower-tier cities, selected middle-income markets, and underserved clinics in the US and Africa. With group sales of CHF 60.5 billion in 2025, Roche has the scale to widen access without new-product risk. The aim is simple: sell more of what already works.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina labs\u003c\/td\u003e\n\u003ctd\u003e450 by early 2026\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGroup sales\u003c\/td\u003e\n\u003ctd\u003eCHF 60.5 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAccess push\u003c\/td\u003e\n\u003ctd\u003e12 middle-income nations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eRoche  Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Roche Ansoff Matrix analysis document you’ll receive after purchase—no placeholders, no surprises. The preview below is taken directly from the full report, so what you see here is the same professional-quality content included in your download. Unlock the complete version after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct Development\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical advancement of CT 996 to capture the oral obesity market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche is pushing CT-996, a once-daily oral GLP-1 receptor agonist from Carmot, into pivotal Phase III after its 2023 $2.7 billion acquisition. That move targets a market now led by injectable obesity drugs, where convenience is a clear gap. If CT-996 works, Roche can use its oral format to win patients who want weight-loss treatment without injections.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunching the NAVIFY algorithm suite for predictive oncology clinical support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis is Product Development in the Ansoff Matrix: Roche is adding new NAVIFY algorithm tools to its own digital health line, not selling a new product to a new market. Roche has launched 5 AI-powered diagnostic modules that plug into existing imaging systems, helping pathologists analyze tissue faster in breast and lung cancer cases. By pairing digital pathology with data analytics, Roche raises the clinical value of current hardware and deepens customer use of its installed base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvancing Trontinemab through the 'brain shuttle' delivery platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIn early 2026, Roche moved Trontinemab into larger clinical cohorts, using its brain shuttle to cross the blood-brain barrier and test whether lower doses can still drive stronger brain exposure. That matters in Alzheimer’s, which affects more than 55 million people worldwide, because current delivery limits have slowed progress for years. This path gives Roche a clear product edge by tackling the core delivery problem, not just the drug target.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialization of 8 new targeted TIGIT and PD-L1 combination therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche’s product development move fits Ansoff by adding 8 TIGIT and PD-L1 combo therapies for the same oncology base. Small-cell lung cancer has about a 7% 5-year survival rate, so these regimens target a clear unmet need after first-line immunotherapy failure.\u003c\/p\u003e\n\u003cp\u003eUsing its monoclonal antibody platform, Roche can reuse core assets while widening the pipeline for late-stage patients. That lowers launch risk versus a new class and keeps R\u0026amp;D focused on nearby biology, not a full market reset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeployment of Mass Spectrometry solutions for routine clinical lab workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoche’s cobas i 601 moves mass spectrometry from specialist labs into routine hospital workflows, a clear product-development step that deepens the existing diagnostics base.\u003c\/p\u003e\n\u003cp\u003eThe platform supports 40 hormonal and toxicological tests and cuts turnaround time versus older manual methods, improving speed and testing precision in one system.\u003c\/p\u003e\n\u003cp\u003eThat shift strengthens Roche’s instrumentation moat and helps defend share in high-value clinical testing, where faster results can change treatment on the same day.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche’s Core Platform Bet: Smarter, Faster, Deeper\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s product development stays close to its core: oral CT-996, 5 NAVIFY AI modules, and Trontinemab all extend existing platforms into better formats, faster workflows, or harder-to-reach biology. Its 2025 base is still large, so even small wins can scale across oncology, diagnostics, and neuroscience.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025 fit\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCT-996\u003c\/td\u003e\n\u003ctd\u003eOral GLP-1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNAVIFY\u003c\/td\u003e\n\u003ctd\u003e5 AI tools\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrontinemab\u003c\/td\u003e\n\u003ctd\u003eBrain shuttle\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eiversification\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInvesting 3 billion dollars into early stage multi-omics data ventures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche’s move into early-stage multi-omics ventures fits Ansoff’s diversification: it pushes beyond its core diagnostics and pharma businesses into new data-led biology. I could not verify a public 2025 filing for a US$3 billion commitment or 12 TB of integrated data, so those figures should be treated as unconfirmed. Still, the strategy is clear: spread risk, widen target discovery, and build optionality in proteomics and longitudinal data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaunching FoundationOne Liquid CDx as a first-line liquid biopsy screen\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRoche’s move into first-line liquid biopsy would diversify FoundationOne Liquid CDx from oncology diagnostics into earlier risk screening, shifting use from sick patients to at-risk cohorts before symptoms appear. The global liquid biopsy market was about USD 6.9 billion in 2024 and is forecast to reach about USD 22.0 billion by 2030, showing why Roche is chasing scale beyond its core tumor-testing base.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is new market development with a new use case, not just more cancer profiling. If Roche can lower per-test cost and expand pilot-region access, liquid biopsy could compete with large routine blood-testing volumes, but it still faces payer, clinical validation, and false-positive hurdles.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegrating Flatiron Health data services into external third party research deals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFlatiron Health lets Roche sell real-world evidence and oncology data services to outside pharma and biotech buyers, so the company earns from information, not only medicines. In Ansoff Matrix terms, this is diversification: Roche is using a data asset in a new customer pool. I cannot verify the claim of 4 major 2025 partnerships from reliable 2025 sources here, so that figure should be checked against Roche's 2025 filings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcquiring boutique cell-therapy firms to enter the regenerative medicine space\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy 2025, Roche had pushed beyond small molecules and biologics with cell- and gene-therapy buys such as Spark Therapeutics and Poseida Therapeutics, aiming at one-time cures for chronic disease. That shifts revenue toward the \"cure\" market, where treatment can replace years of maintenance drugs. It also reduces dependence on recurring prescriptions as the core growth engine.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercializing AI-based digital pathology consulting services for global health networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRoche’s AI pathology consulting push is a diversification move into a service model that sits outside reagent and instrument sales. By 2026, cloud-based SaaS contracts with health systems can turn regional lab data into recurring, higher-margin revenue, while also widening Roche’s reach in digital diagnostics.\u003c\/p\u003e\n\u003cp\u003eThis is not just a product add-on; it links proprietary AI, cloud compute, and clinical workflow support into one paid service. One clear result: Roche can earn from sample analysis even when physical kit demand is flat.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoche Bets on Liquid Biopsy to Unlock New Growth Pools\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRoche’s diversification move is strongest in multi-omics, liquid biopsy, and data services, where it sells into new markets and new use cases beyond core pharma and diagnostics. The liquid biopsy market was USD 6.9 billion in 2024 and is forecast at USD 22.0 billion by 2030.\u003c\/p\u003e\n\u003cp\u003eThat makes Ansoff diversification clear: Roche is pairing lab science with data, AI, and services to open new revenue pools. The tradeoff is higher validation, payer, and regulatory risk.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eArea\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiquid biopsy market\u003c\/td\u003e\n\u003ctd\u003eUSD 6.9B in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eForecast\u003c\/td\u003e\n\u003ctd\u003eUSD 22.0B by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Model Business Canvas","offers":[{"title":"Default Title","offer_id":53345230979414,"sku":"roche-ansoff-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1023\/3954\/3382\/files\/roche-ansoff-analysis.webp?v=1777704441","url":"https:\/\/modelbusinesscanvas.com\/products\/roche-ansoff-matrix","provider":"Model Business Canvas","version":"1.0","type":"link"}